Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 4/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | CDK8 | P49336 | 5/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281946 | 0.86 | SRC (0.49) | RAF1BRAFKDRCDK8PDGFRA | |
| SCHEMBL282170 | 0.80 | KDR (0.62) | RAF1BRAFKDRPDGFRA | |
| SCHEMBL282309 | 0.73 | CDK8 (0.61) | RAF1BRAFKDRCDK8PDGFRA | |
| SCHEMBL281804 | 0.72 | KDR (0.70) | KDRPDGFRA | |
| SCHEMBL281927 | 0.70 | CDK8 (0.58) | RAF1BRAFKDRCDK8PDGFRA | |
| SCHEMBL282550 | 0.69 | CDK8 (0.61) | RAF1BRAFKDRCDK8 | |
| SCHEMBL13529089 | 0.67 | RAF1 (0.72) | RAF1BRAFKDRCDK8PDGFRA | |
| SCHEMBL16507398 | 0.67 | CDK8 (0.46) | RAF1BRAFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL281945 | 0.67 | KDR (0.57) | RAF1BRAFKDRPDGFRA | |
| SCHEMBL719185 | 0.67 | HSD17B10 (0.48) | SMN1; SMN2KDRCDK8PDGFRAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | claimed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | RAF1 955/4885BRAF 1216/4885NPC1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.